| 前收市價 | 4.3300 |
| 開市 | 4.3300 |
| 買盤 | 4.3400 x 200 |
| 賣出價 | 4.4300 x 200 |
| 今日波幅 | 4.3100 - 4.4800 |
| 52 週波幅 | 4.1800 - 27.3500 |
| 成交量 | |
| 平均成交量 | 1,506,029 |
| 市值 | 153.226M |
| Beta 值 (5 年，每月) | 0.52 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.0800 |
| 業績公佈日 | 2024年8月09日 - 2024年8月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 15.71 |
BenzingaWhat's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?
On Thursday, RAPT Therapeutics Inc. (NASDAQ:RAPT) announced that it has decided to close and unblind both its Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis (AD) and its Phase 2a trial of zelnecirnon in asthma. Both clinical trials were placed on clinical hold by the FDA in February 2024 based on a serious adverse event of liver failure requiring a transplant in one patient in the AD trial. Before the clinical hold was imposed, 229 patients had been enrolled in the Phase 2b AD trial
Insider MonkeyWhat Makes RAPT Therapeutics (RAPT) an Investment Choice?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 9.15% (net), compared to a 12.75% return for the Russell 2000 Growth Index. For the year, the fund returned 15.96% (net) compared to […]
ZacksShould You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
